A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes Meeting Abstract

  

Authors:	Hahn, N. M.; Picus, J.; Bambury, R. M.; Pal, S. K.; Hart, L. L.; Grivas, P.; Milowsky, M. I.; Alva, A. S.; Sonpavde, G.; Mortazavi, A.; Bellmunt, J.; Guancial, E. A.; Gupta, S.; Chao, R. C.; Collier, M. A.; Christensen, J.; Chen, I.; Rosenberg, J. E.
Abstract Title:	A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes
Meeting Title:	51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	15 Suppl.
Meeting Dates:	2015 May 29-Jun 2
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-05-20
Language:	English
ACCESSION:	WOS:000358036904767
PROVIDER:	wos
DOI:	10.1200/jco.2015.33.15_suppl.tps4575
Notes:	Meeting Abstract: TPS4575 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80445